Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Stock Information for Medicus Pharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Medicus Pharma Ltd.

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect(TM) Dataset
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200?g Cohort
Medicus Pharma To Participate in the 38th Annual Roth Conference
Medicus Pharma on Bloomberg World
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.